New approaches to VLP-based vaccines
Alekhya Penumarthi A B and Peter M Smooker A C
+ Author Affiliations
- Author Affiliations
A School of Science, RMIT University
Bundoora, Vic. 3083, Australia
B Email: alekhya.penumarthi@rmit.edu.au
C Email: peter.smooker@rmit.edu.au
Microbiology Australia 38(2) 93-94 https://doi.org/10.1071/MA17038
Published: 24 March 2017
Abstract
Vaccination is a long and established field of research, and outputs from the research have saved countless millions of lives. The early vaccines were developed with scant regard for the immunological mechanisms at play, largely because they were unknown. We are now in a position to use our knowledge of immunology to rationally design vaccines. This article focusses on the use of virus-like particles (VLPs) as vaccines.
References
[1] Crisci, E. et al. (2012) Virus-like particles: the new frontier of vaccines for animal viral infections. Vet. Immunol. Immunopathol. 148, 211–225.| Virus-like particles: the new frontier of vaccines for animal viral infections.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XovVahsbs%3D&md5=6febcaced09c1c5de96d4a18a1e23925CAS |
[2] Kushnir, N. et al. (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31, 58–83.
| Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhslSlsr7F&md5=da83b9c088d654f5522dae2f13b65d0cCAS |
[3] Roldão, A. et al. (2010) Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149–1176.
| Virus-like particles in vaccine development.Crossref | GoogleScholarGoogle Scholar |
[4] Meireles, L.C. et al. (2015) Three decades of hepatitis B control with vaccination. World J. Hepatol. 7, 2127–2132.
| Three decades of hepatitis B control with vaccination.Crossref | GoogleScholarGoogle Scholar |
[5] Macartney, K.K. et al. (2013) Safety of human papillomavirus vaccines: a review. Drug Saf. 36, 393–412.
| Safety of human papillomavirus vaccines: a review.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhsl2nsL7E&md5=a708f477ff1b5fc308946f179d39ce72CAS |
[6] Schiller, J.T. and Lowy, D.R. (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 10, 681–692.
| Understanding and learning from the success of prophylactic human papillomavirus vaccines.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xhtlajs7zK&md5=f0e7339c724bde710423d02559f7d30dCAS |
[7] Burns, N.R. et al. (1992) Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles. EMBO J. 11, 1155–1164.
| 1:CAS:528:DyaK38XhvFSktr4%3D&md5=e8821d1a3cf7bc2137e00b063215ed14CAS |
[8] Gilmour, J.E.M. et al. (1989) A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs). AIDS 3, 717–723.
| A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs).Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3c7kvVGntw%3D%3D&md5=c27750700d9b1c7a6da1fbadbea62ce2CAS |
[9] Roth, J.F. (2000) The yeast Ty virus-like particles. Yeast 16, 785–795.
| The yeast Ty virus-like particles.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3cXlt1Gitrg%3D&md5=be43f7bc5b19c0414697c067e5532352CAS |
[10] Penumarthi, A. et al. (2016) Utilising noval nanoparticles for DNA vaccine delivery. Nanotech, Dubai.
[11] Steinman, R.M. (2007) Dendritic cells: versatile controllers of the immune system. Nat. Med. 13, 1155–1159.
| Dendritic cells: versatile controllers of the immune system.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXhtFagsb3P&md5=5eed900a5bbae9a0887d4212b9abcc09CAS |
[12] Fifis, T. et al. (2004) Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148–3154.
| Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2cXmvVCqtrs%3D&md5=52a1fdd94f648c34c185ce9dd8b76caaCAS |
[13] Braun, H. et al. (1999) Oligonucleotide and plasmid DNA packaging into polyoma VPI virus-like particles expressed in Escherichia coli. Biotechnol. Appl. Biochem. 29, 31–43.
| 1:CAS:528:DyaK1MXhsFyqtb8%3D&md5=efdc976f0dfc60c24386bed3383c8cc1CAS |
[14] Liu, Y. et al. (2001) Efficiency of delivery of DNA to cells by bovine papillomavirus type-1 L1/L2 pseudovirions. Appl. Microbiol. Biotechnol. 56, 150–156.
| Efficiency of delivery of DNA to cells by bovine papillomavirus type-1 L1/L2 pseudovirions.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3MXls1ShtL4%3D&md5=ea90353a7c54113efd5bdf97f8c3f2e6CAS |
[15] Touze, A. and Coursaget, P. (1998) In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26, 1317–1323.
| In vitro gene transfer using human papillomavirus-like particles.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK1cXhvFejs7k%3D&md5=cf4d4757f5dcb6af779945b3900d7823CAS |
[16] Hoque, M. et al. (1999) Chimeric virus-like particle formation of adeno-associated virus. Biochem. Biophys. Res. Commun. 266, 371–376.
| Chimeric virus-like particle formation of adeno-associated virus.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK1MXnvFersL4%3D&md5=0e5a4092e829f581fbf3545fd11e4140CAS |
[17] Gedvilaite, A. et al. (2000) Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 273, 21–35.
| Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3cXks1Omtr0%3D&md5=2ebe8e62e11d67156b288d42336a90b8CAS |
[18] Tsoka, S. et al. (2000) Selective flocculation and precipitation for the improvement of virus-like particle recovery from yeast homogenate. Biotechnol. Prog. 16, 661–667.
| Selective flocculation and precipitation for the improvement of virus-like particle recovery from yeast homogenate.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3cXjtlygsbo%3D&md5=383177d80d229abe0536df5b31f9bda8CAS |
[19] Maranga, L. et al. (2004) Scale-up of virus-like particles production: effects of sparging, agitation and bioreactor scale on cell growth, infection kinetics and productivity. J. Biotechnol. 107, 55–64.
| Scale-up of virus-like particles production: effects of sparging, agitation and bioreactor scale on cell growth, infection kinetics and productivity.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3sXpvF2htrY%3D&md5=9b44a22f178bd27cce5b3eb936108c31CAS |
[20] Ambühl, P.M. et al. (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertens. 25, 63–72.
| A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.Crossref | GoogleScholarGoogle Scholar |
[21] Grgacic, E.V.L. and Anderson, D.A. (2006) Virus-like particles: passport to immune recognition. Methods 40, 60–65.
| Virus-like particles: passport to immune recognition.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XpvFGhsro%3D&md5=c0e5e8b066568674e45f4fadf523180cCAS |
